1
|
Bottari G, Caruso M, Paionni E, De Luca M, Romani L, Pisani M, Grandin A, Gargiullo L, Zampini G, Gagliardi C, Fegatelli DA, Vestri A, Lancella L, Porzio O, Muda AO, Villani A, Atti MCD, Raponi M, Cecchetti C. Accuracy of Pancreatic Stone Protein for diagnosis of sepsis in children admitted to pediatric intensive care or high-dependency care: a pilot study. Ital J Pediatr 2023; 49:134. [PMID: 37805604 PMCID: PMC10559422 DOI: 10.1186/s13052-023-01540-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Accepted: 09/25/2023] [Indexed: 10/09/2023] Open
Abstract
BACKGROUND Pancreatic Stone Protein (PSP) is one of the most promising diagnostic and prognostic markers. The aim of the study was to assess the accuracy of PSP, compared to C-Reactive Protein (CRP), and Procalcitonin (PCT) for sepsis diagnosis in pediatric patients. Furthermore, we explored the correlation of PSP levels with sepsis severity and organ failure measured with PELOD-2 score. METHODS Forty pediatric patients were enrolled following admission to pediatric intensive care, high dependency care or pediatric ward. PSP blood levels were measured in Emergency Department (nanofluidic point-of-care immunoassay; abioSCOPE, Abionic SA, Switzerland) on day 1, 2, 3, 5 and 7 from the onset of the clinical signs and symptoms of sepsis or SIRS. Inclusion criteria were: 1) patient age (1 month to 18 years old), 2) signs and symptoms of SIRS, irrespective of association with organ dysfunction. Exclusion criteria were: 1) hemato-oncological diseases and/or immunodeficiencies, 2) pancreatic diseases. RESULTS Septic patients showed higher PSP levels than those with non-infectious systemic inflammation. The optimal cut-off in diagnosis of sepsis for PSP at day 1 was 167 ng/ml resulted in a sensitivity of 59% (95% IC 36%-79%) and a specificity of 83% (95% IC 58%-96%) with an AUC of 0.636 for PSP in comparison to AUC of 0.722 for PCT and 0.503 for C-RP. ROC analysis for outcome (survival versus no survival) has showed AUC 0.814 for PSP; AUC 0.814 for PCT; AUC of 0.657 for C-RP. CONCLUSIONS PSP could distinguish sepsis from non-infectious systemic inflammation; however, our results need to be confirmed in larger pediatric population.
Collapse
Affiliation(s)
- Gabriella Bottari
- Pediatric Intensive Care Unit, Bambino Gesù Children's Hospital, IRCSS, Piazza Sant'Onofrio 4, 00165, Rome, Italy.
| | - Mariangela Caruso
- Department of Anesthesia and Intensive Care, Catholic University of Rome, Residency School of Anesthesia and Intensive Care, Catholic University, Rome, Italy
| | - Emanuel Paionni
- Clinical Laboratory Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Maia De Luca
- Infectious Disease Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy
| | - Lorenza Romani
- Infectious Disease Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy
| | - Mara Pisani
- Pediatric Emergency Medicine, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Annalisa Grandin
- General Pediatric and Infectious Disease Unit, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy
| | - Livia Gargiullo
- General Pediatric and Infectious Disease Unit, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy
| | - Giorgio Zampini
- Pediatric Intensive Care Unit, Bambino Gesù Children's Hospital, IRCSS, Piazza Sant'Onofrio 4, 00165, Rome, Italy
| | - Chiara Gagliardi
- Pediatric Intensive Care Unit, Bambino Gesù Children's Hospital, IRCSS, Piazza Sant'Onofrio 4, 00165, Rome, Italy
| | - Danilo Alunni Fegatelli
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185, Rome, Italy
| | - Annarita Vestri
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185, Rome, Italy
| | - Laura Lancella
- Infectious Disease Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy
| | - Ottavia Porzio
- Clinical Laboratory Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Andrea Onetti Muda
- Clinical Laboratory Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
- Scientific Direction, Bambino Gesù Children's Hospital, Rome, Italy
| | - Alberto Villani
- General Pediatric and Infectious Disease Unit, Pediatric Emergency Medicine, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Marta Ciofi Degli Atti
- Clinical Pathways and Epidemiology Unit-Medical Direction, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | | | - Corrado Cecchetti
- Pediatric Intensive Care Unit, Bambino Gesù Children's Hospital, IRCSS, Piazza Sant'Onofrio 4, 00165, Rome, Italy
| |
Collapse
|
2
|
Cannarella R, Caruso M, Condorelli RA, Timpanaro TA, Caruso MA, La Vignera S, Calogero AE. Testicular volume in 268 children and adolescents followed-up for childhood obesity-a retrospective cross-sectional study. Eur J Endocrinol 2023; 188:331-342. [PMID: 37127298 DOI: 10.1093/ejendo/lvad033] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 12/21/2022] [Accepted: 03/06/2023] [Indexed: 05/03/2023]
Abstract
CONTEXT Prevalence of obesity in childhood has increased over the past few decades. The impact of obesity and of obesity-related metabolic disorders on testicular growth is unknown. OBJECTIVE To evaluate the impact of obesity, hyperinsulinemia, and insulin resistance on testicular volume (TV) in pre-pubertal (<9 years), peri-pubertal (9-14 years), and post-pubertal (14-16 years) periods. METHODS We collected data on TV, age, standard deviation score (SDS) of the body mass index (BMI), insulin, and fasting glycemia in 268 children and adolescents followed-up for weight control. RESULTS Peri-pubertal boys with normal weight had a significantly higher TV compared to those with overweight or obesity. No difference was found in the other age ranges when data were grouped according to BMI. Pre- and post-pubertal children/adolescents with normal insulin levels had significantly higher TV compared to those with hyperinsulinemia. Peri-pubertal boys with hyperinsulinemia had significantly higher TV compared to those with normal insulin levels. Post-pubertal adolescents with insulin resistance had lower TV and peri-pubertal boys had higher TV compared to those without insulin resistance. No difference was found in pre-puberty. CONCLUSIONS Closer control of the body weight and the associated metabolic alterations in childhood and adolescence may maintain testicular function later in life.
Collapse
Affiliation(s)
- R Cannarella
- Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - M Caruso
- Pediatric Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - R A Condorelli
- Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - T A Timpanaro
- Pediatric Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - M A Caruso
- Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - S La Vignera
- Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| | - A E Calogero
- Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy
| |
Collapse
|
3
|
Caruso M, Lembo MA, Cozzi G. Girl with genital bleeding and dysuria. Arch Emerg Med 2022; 39:600-633. [PMID: 35858684 DOI: 10.1136/emermed-2020-210848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/10/2021] [Indexed: 11/03/2022]
Affiliation(s)
- Mariangela Caruso
- Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy
| | - Maria Antonietta Lembo
- Department of Surgery, Institute for Maternal and Child Health-IRCCS Burlo Garofolo, Trieste, Italy
| | - Giorgio Cozzi
- Emergency Department, Institute for Maternal and Child Health-IRCCS Burlo Garofolo, Trieste, Italy
| |
Collapse
|
4
|
Caruso M, Gastaldi L, Pastorelli S, Cereatti A, Digo E. An ISB-consistent Denavit-Hartenberg model of the human upper limb for joint kinematics optimization: validation on synthetic and robot data during a typical rehabilitation gesture. Annu Int Conf IEEE Eng Med Biol Soc 2022; 2022:1805-1808. [PMID: 36085675 DOI: 10.1109/embc48229.2022.9871201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Several biomedical contexts such as diagnosis, rehabilitation, and ergonomics require an accurate estimate of human upper limbs kinematics. Wearable inertial measurement units (IMU s) represent a suitable solution because of their unobtrusiveness, portability, and low-cost. However, the time-integration of the gyroscope angular velocity leads to an unbounded orientation drift affecting both angular and linear displacements over long observation interval. In this work, a Denavit-Hartenberg model of the upper limb was defined in accordance with the guidelines of the International Society of Biomechanics and exploited to design an optimization kinematics process. This procedure estimated the joint angles by minimizing the difference between the modelled and IMU-driven orientation of upper arm and forearm. In addition, reasonable constraints were added to limit the drift influence on the final joint kinematics accuracy. The validity of the procedure was tested on synthetic and experimental data acquired with a robotic arm over 20 minutes. Average rms errors amounted to 2.8 deg and 1.1 for synthetic and robot data, respectively. Clinical Relevance - The proposed method has the potential to improve robustness and accuracy of multi-joint kinematics estimation in the general contexts of home-based tele-rehabilitation interventions. In this respect adoption of multi-segmental kinematic model along with physiological joint constraints could contribute to address current limitations associated to unsupervised analysis in terms of monitoring and outcome assessment.
Collapse
|
5
|
Serretta V, Scalici Gesolfo C, Gebbia V, Borsellino N, Di Trapani D, Ferrera G, Spada M, Armenio A, Lamartina M, Valerio M, Di Grazia A, Pennisi M, Caruso M, Ruoppolo M, Barbera M, Adamo V, Cimino S, Firenze A, Piazza D, Macchiarella V, Fazio I, La Vecchia M. Virtual multi-institutional tumor board: Feasibility and physicians acceptance, a GSTU foundation project in Sicily. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00181-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
6
|
Felli C, Baldassarre A, Uva P, Alisi A, Cangelosi D, Ancinelli M, Caruso M, Paolini A, Montano A, Silano M, Vincentini O, Catassi C, Lionetti E, Gatti S, Ferretti F, Masotti A. Circulating microRNAs as novel non-invasive biomarkers of paediatric celiac disease and adherence to gluten-free diet. EBioMedicine 2022; 76:103851. [PMID: 35151110 PMCID: PMC8842006 DOI: 10.1016/j.ebiom.2022.103851] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 01/04/2022] [Accepted: 01/17/2022] [Indexed: 12/11/2022] Open
Abstract
Background Celiac Disease (CD) is a multifactorial autoimmune enteropathy (with a prevalence of approximately 1% worldwide) that exhibits a wide spectrum of clinical, serological and histological manifestations. For the diagnosis of paediatric CD, the gold standard is the combination of serological tests (with high TGA-IgA values greater than 10 times the upper limit of normal) and duodenal biopsy (with a positive TGA-IgA but low titer). Therefore, a diagnostic test that totally excludes an invasive approach has not been discovered so far and the discovery of novel biological markers would represent an undoubted advantage for the diagnosis of CD and prognostic evaluation. MicroRNAs (miRNAs), small non-coding RNAs (18–22 nucleotides) that regulate gene expression at post-transcriptional level and play important roles in many biological processes, represent a novel class of potential disease biomarkers. Their presence in biological fluids (i.e., serum, plasma, saliva, urine) provides the opportunity to employ circulating miRNAs as novel non-invasive biomarkers. Methods In our prospective observational study, we examined the expression of circulating miRNAs in a cohort of CD patients (both at diagnosis and on gluten-free diet, respectively referred as CD and GFD) compared to healthy controls. By small RNA-Seq we discovered a set of circulating miRNAs that were further validated by qPCR with specific assays. Findings We found that out of the 13 miRNAs able to discriminate the three groups (i.e., CD, GFD and controls), three of them, namely miR-192-5p, miR-215-5p and miR-125b-5p (alone or in combination), were able to discriminate these three groups with high accuracy and specificity. Interpretation Our conclusions emphasize that these circulating miRNAs can be employed not only for the diagnosis of CD patients with a low TGA-IgA titer but also to monitor the adherence to a gluten-free diet by CD patients. In conclusion, we suggest the use of the circulating miRNAs identified in this work as a novel diagnostic and follow-up tool for paediatric CD. Funding This work was supported by Fondazione Celiachia Onlus (FC) Grant n° 018/FC/2013 and by Italian Ministry of Health (Ricerca Corrente).
Collapse
Affiliation(s)
- Cristina Felli
- Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy
| | | | - Paolo Uva
- Clinical Bioinformatics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Anna Alisi
- Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy; Research Unit of Molecular Genetics of Complex Phenotypes, Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy
| | - Davide Cangelosi
- Clinical Bioinformatics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Monica Ancinelli
- Hepato-Gastroenterology and Nutrition Department, Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy
| | - Mariangela Caruso
- Department of Maternal Infantile and Urological Sciences, SAPIENZA University of Rome, Rome, Italy
| | - Alessandro Paolini
- Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy
| | - Alessia Montano
- Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy
| | - Marco Silano
- Unit of Human Nutrition and Health, Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, Rome, Italy
| | - Olimpia Vincentini
- Unit of Human Nutrition and Health, Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, Rome, Italy
| | - Carlo Catassi
- Department of Pediatrics, Polytechnic University of Marche, Ancona, Italy
| | - Elena Lionetti
- Department of Pediatrics, Polytechnic University of Marche, Ancona, Italy
| | - Simona Gatti
- Department of Pediatrics, Polytechnic University of Marche, Ancona, Italy
| | - Francesca Ferretti
- Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy; Research Unit of Molecular Genetics of Complex Phenotypes, Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy
| | - Andrea Masotti
- Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.
| |
Collapse
|
7
|
Salis F, Bertuletti S, Scott K, Caruso M, Bonci T, Buckley E, Croce UD, Mazza C, Cereatti A. A wearable multi-sensor system for real world gait analysis. Annu Int Conf IEEE Eng Med Biol Soc 2021; 2021:7020-7023. [PMID: 34892719 DOI: 10.1109/embc46164.2021.9630392] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Gait analysis is commonly performed in standardized environments, but there is a growing interest in assessing gait also in ecological conditions. In this regard, an important limitation is the lack of an accurate mobile gold standard for validating any wearable system, such as continuous monitoring devices mounted on the trunk or wrist. This study therefore deals with the development and validation of a new wearable multi-sensor-based system for digital gait assessment in free-living conditions. In particular, results obtained from five healthy subjects during lab-based and real-world experiments were presented and discussed. The in-lab validation, which assessed the accuracy and reliability of the proposed system, shows median percentage errors smaller than 2% in the estimation of spatio-temporal parameters. The system also proved to be easy to use, comfortable to wear and robust during the out-of-lab acquisitions, showing its feasibility for free-living applications.
Collapse
|
8
|
Polosa R, Emma R, Cibella F, Caruso M, Conte G, Benfatto F, Ferlito S, Gulino A, Malerba M, Caponnetto P. Impact of exclusive e-cigarettes and heated tobacco products use on muco-ciliary clearance. Ther Adv Chronic Dis 2021; 12:20406223211035267. [PMID: 34422253 PMCID: PMC8371723 DOI: 10.1177/20406223211035267] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Accepted: 07/07/2021] [Indexed: 11/29/2022] Open
Abstract
Background: Tobacco smoking impairs mucociliary clearance (MCC) efficiency as shown by
prolonged saccharin test transit time (STTT). Avoiding exposure to tobacco
smoke from combustible cigarettes may restore MCC function and former
smokers have been shown to exhibit similar STTT as never smokers. The impact
on STTT of switching from smoking to combustion-free tobacco products such
as e-cigarettes (ECs) and heated tobacco products (HTPs) is not known. Methods: We report STTT of exclusive EC and HTP users. Test results were compared with
those obtained in current, former, and never smokers. Results: STTT were obtained from 39 current, 40 former, 40 never smokers, and from 20
EC and 20 HTP users. Comparison of STTT values showed significant difference
among the five study groups (p < 0.00001) with current
smokers having a median [interquartile range (IQR)] STTT of 13.15 min, which
was significantly longer compared with that of all other study groups. In
particular, compared with former (7.26 min) and never smokers (7.24 min),
exclusive EC users and exclusive HTP users had similar STTT at 7.00 and
8.00 min, respectively. Conclusion: Former smokers who have switched to exclusive regular use of combustion-free
nicotine delivery systems (i.e., ECs and HTPs) exhibit similar saccharin
transit time as never and former smokers. This suggests that combustion-free
nicotine delivery technologies are unlikely to have detrimental effects on
MCC function.
Collapse
Affiliation(s)
- R Polosa
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Italy Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
| | - R Emma
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy, Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Catania, Italy
| | - F Cibella
- National Research Council of Italy, Institute of Biomedicine and Molecular Immunology, Palermo, Italy
| | - M Caruso
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy, Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Catania, Italy
| | - G Conte
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy
| | - F Benfatto
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy
| | - S Ferlito
- Department of Medical Science, Surgical Science and advanced Technologies G.F, Ingrassia, University of Catania, Catania, Italy
| | - A Gulino
- Department of Medical Science, Surgical Science and advanced Technologies G.F, Ingrassia, University of Catania, Catania, Italy
| | - M Malerba
- Translational Medicine Department, Eastern Piedmont University (UPO), Novara, Italy
| | - P Caponnetto
- Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital Policlinico - V. Emanuele, University of Catania, Catania, Italy, Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Catania, Italy
| |
Collapse
|
9
|
Rizza S, Pietroiusti A, Farcomeni A, Mina GG, Caruso M, Virgilio M, Magrini A, Federici M, Coppeta L. Monthly fluctuations in 25-hydroxy-vitamin D levels in day and rotating night shift hospital workers. J Endocrinol Invest 2020; 43:1655-1660. [PMID: 32342444 DOI: 10.1007/s40618-020-01265-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Accepted: 04/17/2020] [Indexed: 12/14/2022]
Abstract
PURPOSE Epidemiological studies have suggested that indoor hospital employees, either day or night shift workers, are at high risk of metabolic and cardiovascular diseases. Interestingly, previous reports have also described a higher prevalence of vitamin D (25OHD) deficiency among these workers. However, few studies have determined the monthly variations in 25OHD levels in indoor hospital employees. METHODS To address this lack of knowledge, in 2018, during the periodic health surveillance checks at the Service of Occupational Medicine, we measured 25OHD levels in a group of indoor hospital workers (88 rotating night shift workers vs 200 day workers). Each participant received a single annual health surveillance check. RESULTS The mean levels of 25OHD were consistently below the lower limit of the normal range in both groups throughout the year. Only in the summer, day workers but not rotating night shift workers (mean 25.9 ± 11.3 ng/ml vs 23.1 ± 9.1 ng/ml; p = 0.042) showed levels significantly higher than those in the other seasons. This difference remained statistically significant even after correction for study covariates [β = - 1.649 (CI - 0.283/- 3.482), p = 0.039]. A cosinor analysis confirmed that the difference in the 25OHD levels between groups was present later in the year. CONCLUSIONS We found that relatively young healthy hospital workers, especially those with rotating night shifts, in the absence of significant metabolic risk factors, have a high risk of 25OHD deficiency/insufficiency. Because 25OHD deficiency may lead to a progression to more severe conditions such as osteoporosis or bone fractures, our results should be verified in larger cohorts including different ancestries.
Collapse
Affiliation(s)
- S Rizza
- Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
| | - A Pietroiusti
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| | - A Farcomeni
- Department of Economics and Finance, University of Rome Tor Vergata, Rome, Italy
| | - G G Mina
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| | - M Caruso
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| | - M Virgilio
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| | - A Magrini
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| | - M Federici
- Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
| | - L Coppeta
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy
| |
Collapse
|
10
|
Zedda A, Gusai E, Caruso M, Bertuletti S, Baldazzi G, Spanu S, Riboni D, Pibiri A, Monticone M, Cereatti A, Pani D. DoMoMEA: a Home-Based Telerehabilitation System for Stroke Patients. Annu Int Conf IEEE Eng Med Biol Soc 2020; 2020:5773-5776. [PMID: 33019286 DOI: 10.1109/embc44109.2020.9175742] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
After a cerebral stroke, survivors need to follow a neurorehabilitation program including exercises to be executed under a therapist's supervision or autonomously. Technological solutions are needed to support the early discharge of the patients just after the primary hospital treatments, by still providing an adequate level of rehabilitation. The DoMoMEA Project proposes a fully-wearable m-health solution able to administer a neurorehabilitation therapy in the patient's home or every other place established by the patient for a rehabilitation session. The exploitation of magneto-inertial measurement units only, wirelessly connected to an Android-operated device, provides robustness to different operating conditions and immunity to optical occlusion problems, compared to RGB-D cameras. Patients' engagement is fostered by the exploitation of the exergame version of the ten rehabilitation exercises, implemented in Unity 3D. Store-and-forward telemonitoring features, supported by cloud-based storage and by a web application accessible from anywhere by medical personnel and patients, enable constant transparent monitoring of the rehabilitation progresses. The clinical trial of the DoMoMEA telerehabilitation system will involve 40 post-stroke patients with mild impairment and will start as soon as the restrictions due to the COVID-19 pandemic will allow to enroll patients.
Collapse
|
11
|
Caruso M, Sabatini AM, Knaflitz M, Gazzoni M, Croce UD, Cereatti A. Accuracy of the Orientation Estimate Obtained Using Four Sensor Fusion Filters Applied to Recordings of Magneto-Inertial Sensors Moving at Three Rotation Rates. Annu Int Conf IEEE Eng Med Biol Soc 2020; 2019:2053-2058. [PMID: 31946305 DOI: 10.1109/embc.2019.8857655] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Magneto-Inertial technology is a well-established alternative to optical motion capture for human motion analysis applications since it allows prolonged monitoring in free-living conditions. Magneto and Inertial Measurement Units (MIMUs) integrate a triaxial accelerometer, a triaxial gyroscope and a triaxial magnetometer in a single and lightweight device. The orientation of the body to which a MIMU is attached can be obtained by combining its sensor readings within a sensor fusion framework. Despite several sensor fusion implementations have been proposed, no well-established conclusion about the accuracy level achievable with MIMUs has been reached yet. The aim of this preliminary study was to perform a direct comparison among four popular sensor fusion algorithms applied to the recordings of MIMUs rotating at three different rotation rates, with the orientation provided by a stereophotogrammetric system used as a reference. A procedure for suboptimal determination of the parameter filter values was also proposed. The findings highlighted that all filters exhibited reasonable accuracy (rms errors <; 6.4°). Moreover, in accordance with previous studies, every algorithm's accuracy worsened as the rotation rate increased. At the highest rotation rate, the algorithm from Sabatini (2011) showed the best performance with errors smaller than 4.1° rms.
Collapse
|
12
|
De Marzo V, Parisi AR, Donahue M, D'Amario D, Annibali G, Manganiello V, Caruso M, Ielasi A, Misuraca L, Altamura L, Cortese B, Canepa M, Porto I. P2801Hard events after orsiro sirolimus-eluting stent (HEROES) in STEMI: a multicenter registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Primary percutaneous coronary intervention (pPCI) using drug-eluting stents (DES) is the treatment of choice for the ST segment elevation Myocardial infarction (STEMI). Specific DES platforms, as well the strategies used to control drug release, may influence mid-to-long term pPCI success rate.
Orsiro, a third generation hybrid sirolimus eluting stent with a biodegradable polymer, may potentially cause less stent malapposition, stent-induced inflammation and mechanical damage, ultimately reducing the thrombogenicity of the stent.
Purpose
The aim of the HEROES Registry is: 1) to evaluate the safety and efficacy of the Orsiro stent in STEMI patients undergoing pPCI; 2) to capture data that reflect the “real-world” use of Orsiro stents in pPCI and provide insights into patient characteristics, comorbid conditions, patterns of care, quality of care and performance measurements.
Methods
From January 2012 to March 2018 we prospectively enrolled all patients diagnosed with STEMI who have received one or more Orsiro stents in the target vessel of pPCI at 9 Italian centres.
The primary end-point of the study was a device-oriented composite end-point (DOCE) of cardiac death, any myocardial infarction (MI) clearly attributable to the intervention culprit vessel (TVMI) and ischemic-driven target lesion revascularization (ID-TLR) at 1-year follow up.
Secondary end-points were: 1) DOCE at 6-month and 3-year follow-ups; 2) any definite/probable stent thrombosis; 3) any TIMI major bleeding (in-hospital, within 7 days after pPCI and at follow-up).
Results
Study cohort comprised 338 patients with a mean age of 64.9±12.0 years; 255 (75.4%) were men, 69 (20.4%) had diabetes and 59 (17.5%) chronic kidney disease. Median follow-up was 10.5 (range 0–67) months. Culprit vessel was the left anterior descending (LAD) in 167 (49.4%), right coronary (RCA) in 97 (28.7%), left circumflex artery (LCX) in 42 (12.4%) and other vessels in 32 (9.5%). Multivessel disease was present in 178 (52.7%); 106 (31.4%) had bifurcation lesion as a culprit. In 155 (45.9%) the culprit lesion was proximal, in 154 (45.6%) mid-vessel. Stent per lesion ratio was 1.3±0.6. Thrombus grade was 0–2 in 236 (69.8%) and 3–5 in 102 (30.2%).
At 1-year follow-up we observed a 4.4% cumulative incidence of DOCE, consisting of 13 (3.8%) cardiac deaths, 1 (0.3%) TVMI and 1 (0.3%) ID-TLR. Definite stent thrombosis occurred in only 1 (0.3%) patient during hospital stay. There were only 4 major bleedings (1.2%), all during follow-up.
Kaplan-Meier analysis showed a DOCE-free survival at 6 months of 95.9%, and at 1 and 3 years of 95.6 and 95%, respectively.
DOCE-free survival curve
Conclusions
Orsiro stent seems to be effective and safe in contemporary pPCI. The optimal features of Orsiro contribute to the few adverse events observed during follow-up and to an event-free survival that compares favorably with similar registries of modern DES.
Collapse
Affiliation(s)
| | - A R Parisi
- AO Ospedali Riuniti Marche Nord, Pesaro, Italy
| | - M Donahue
- Polyclinic Casilino of Rome, Rome, Italy
| | - D D'Amario
- Polyclinic Agostino Gemelli, Rome, Italy
| | - G Annibali
- Polyclinic Agostino Gemelli, Rome, Italy
| | | | | | - A Ielasi
- Bolognini Hospital, Seriate, Italy
| | | | | | - B Cortese
- Fatebenefratelli Hospital, Milan, Italy
| | - M Canepa
- San Martino Hospital, Genova, Italy
| | - I Porto
- San Martino Hospital, Genova, Italy
| |
Collapse
|
13
|
Sahlem G, Caruso M, Malcolm R, George M, McRae-Clark A. A case series exploring the effect of twenty sessions of repetitive transcranial magnetic stimulation (rTMS) on cannabis use and craving. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
14
|
Tariq K, Schofield JPR, Nicholas BL, Burg D, Brandsma J, Bansal AT, Wilson SJ, Lutter R, Fowler SJ, Bakke, Caruso M, Dahlen B, Horváth I, Krug N, Montuschi P, Sanak M, Sandström T, Geiser T, Pandis I, Sousa AR, Adcock IM, Shaw DE, Auffray C, Howarth PH, Sterk PJ, Chung KF, Skipp PJ, Dimitrov B, Djukanović R. Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma. Respir Med 2019; 150:66-73. [PMID: 30961953 DOI: 10.1016/j.rmed.2019.02.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 01/30/2019] [Accepted: 02/04/2019] [Indexed: 01/08/2023]
Abstract
Gastro-oesophageal reflux disease (GORD) has long been associated with poor asthma control without an established cause-effect relationship. 610 asthmatics (421 severe/88 mild-moderate) and 101 healthy controls were assessed clinically and a subset of 154 severe asthmatics underwent proteomic analysis of induced sputum using untargeted mass spectrometry, LC-IMS-MSE. Univariate and multiple logistic regression analyses (MLR) were conducted to identify proteins associated with GORD in this cohort. When compared to mild/moderate asthmatics and healthy individuals, respectively, GORD was three- and ten-fold more prevalent in severe asthmatics and was associated with increased asthma symptoms and oral corticosteroid use, poorer quality of life, depression/anxiety, obesity and symptoms of sino-nasal disease. Comparison of sputum proteomes in severe asthmatics with and without active GORD showed five differentially abundant proteins with described roles in anti-microbial defences, systemic inflammation and epithelial integrity. Three of these were associated with active GORD by multiple linear regression analysis: Ig lambda variable 1-47 (p = 0·017) and plasma protease C1 inhibitor (p = 0·043), both in lower concentrations, and lipocalin-1 (p = 0·034) in higher concentrations in active GORD. This study provides evidence which suggests that reflux can cause subtle perturbation of proteins detectable in the airways lining fluid and that severe asthmatics with GORD may represent a distinct phenotype of asthma.
Collapse
Affiliation(s)
- K Tariq
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Clinical Experimental Sciences Unit, Faculty of Medicine, University of Southampton, University Hospital Southampton, South Academic Block, Southampton, UK
| | - J P R Schofield
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Centre for Proteomic Research, University of Southampton, Highfield, Southampton, UK
| | - B L Nicholas
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Clinical Experimental Sciences Unit, Faculty of Medicine, University of Southampton, University Hospital Southampton, South Academic Block, Southampton, UK
| | - D Burg
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Centre for Proteomic Research, University of Southampton, Highfield, Southampton, UK
| | - J Brandsma
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK
| | | | - S J Wilson
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK
| | - R Lutter
- AMC, Department of Experimental Immunology, University of Amsterdam, Amsterdam, the Netherlands; AMC, Department of Respiratory Medicine, University of Amsterdam, Amsterdam, the Netherlands
| | - S J Fowler
- Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and University Hospital of South Manchester, NHS Foundation Trust, Manchester, UK
| | - Bakke
- Department of Clinical Science, University of Bergen, Bergen, Norway
| | - M Caruso
- Dept. of Clinical and Experimental Medicine Hospital University, Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy
| | - B Dahlen
- Division of Respiratory Medicine and Allergy, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - I Horváth
- Dept. of Pulmonology, Semmelweis University, Budapest, Hungary
| | - N Krug
- Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Hannover, Germany
| | - P Montuschi
- Dept. of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy
| | - M Sanak
- Division of Molecular Biology and Clinical Genetics, Medical College, Jagiellonian University Medical College, Krakow, Poland
| | - T Sandström
- Dept. of Medicine, Dept of Public Health and Clinical Medicine Respiratory Medicine Unit, Umeå University, Umeå, Sweden
| | - T Geiser
- University Hospital Bern, Bern, Switzerland
| | - I Pandis
- Data Science Institute, Imperial College, London, UK
| | - A R Sousa
- Respiratory Therapeutic Unit, GSK, Stockley Park, UK
| | - I M Adcock
- Cell and Molecular Biology Group, Airways Disease Section, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London, UK
| | - D E Shaw
- Respiratory Research Unit, University of Nottingham, Nottingham, UK
| | - C Auffray
- European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France
| | - P H Howarth
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Clinical Experimental Sciences Unit, Faculty of Medicine, University of Southampton, University Hospital Southampton, South Academic Block, Southampton, UK
| | - P J Sterk
- AMC, Department of Respiratory Medicine, University of Amsterdam, Amsterdam, the Netherlands
| | - K F Chung
- Airways Disease, National Heart and Lung Institute, Imperial College, London & Royal Brompton NIHR Biomedical Research Unit, London, United Kingdom
| | - P J Skipp
- Centre for Proteomic Research, University of Southampton, Highfield, Southampton, UK
| | - B Dimitrov
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK
| | - R Djukanović
- NIHR Southampton Respiratory Biomedical Research Centre, University Hospital Southampton, Southampton, UK; Clinical Experimental Sciences Unit, Faculty of Medicine, University of Southampton, University Hospital Southampton, South Academic Block, Southampton, UK.
| | | |
Collapse
|
15
|
Radtke A, Caruso M, Miller A, Getman L. Treatment of a poorly differentiated sarcoma in the oropharynx of a horse. EQUINE VET EDUC 2018. [DOI: 10.1111/eve.13025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- A. Radtke
- Department of Clinical Sciences Cornell University College of Veterinary Medicine Ithaca New York USA
| | - M. Caruso
- Tennessee Equine Hospital Thompson's Station Tennessee USA
| | - A. Miller
- Department of Biomedical Sciences Section of Anatomic Pathology Cornell University College of Veterinary Medicine Ithaca New York USA
| | - L. Getman
- Tennessee Equine Hospital Thompson's Station Tennessee USA
| |
Collapse
|
16
|
Adamo V, Ricciardi G, Schifano S, Russo A, Gebbia V, Blasi L, Giuffrida D, Scandurra G, Savarino A, Butera A, Borsellino N, Verderame F, Caruso M. Nab-paclitaxel (nab-P) in metastatic breast cancer (MBC) in elderly patients: A real life setting (NEREIDE study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Adamo V, Ricciardi G, Schifano S, Russo A, Gebbia V, Blasi L, Giuffrida D, Scandurra G, Savarino A, Butera A, Borsellino N, Verderame F, Caruso M. Safety and efficacy of the treatment with Nab-paclitaxel in mEtastaticbREast cancer In elDerlypatiEnts: NEREIDE Study. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30567-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Dakiw Piaceski A, Larouche D, Ghani K, Bisson F, Cortez Ghio S, Larochelle S, Moulin VJ, Caruso M, Germain L. Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa. Eur Cell Mater 2018; 35:73-86. [PMID: 29441510 DOI: 10.22203/ecm.v035a06] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The combination of gene therapy and tissue engineering is one of the most promising strategies for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a rare genetic disease characterised by mutations in the COL7A1 gene, encoding type VII collagen (COLVII), which forms anchoring fibrils at the dermal-epidermal junction of the skin. This disease causes severe blistering and only palliative treatments are offered. In this study, the base of a strategy combining gene therapy and a tissue-engineered skin substitute (TES), which would be suitable for the permanent closure of skin wounds, was set-up. As a high transduction efficiency into fibroblasts and/or keratinocytes seems to be a prerequisite for a robust and sustained correction of RDEB, different envelope pseudotyped retroviral vectors and the transduction enhancer EF-C were tested. When green fluorescent protein (GFP) was used as a reporter gene to evaluate the retroviral-mediated gene transfer, the fibroblast infection efficiency was 30 % higher with the Ampho pseudotyped vector as compared with the other pseudotypes. At least a 3.1-fold and a 1.3-fold increased transduction were obtained in fibroblasts and keratinocytes, respectively, with EF-C as compared with polybrene. A continuous and intense deposit of haemagglutinin (HA)-COLVII was observed at the dermal-epidermal junction of self-assembled TESs made of cells transduced with a HA-tagged COL7A1 vector. Furthermore, HA-tagged basal epidermal cells expressing keratin 19 were observed in TESs, suggesting stem cell transduction. This approach could be a valuable therapeutic option to further develop, in order to improve the long-term life quality of RDEB patients.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - M Caruso
- Cancer Research Centre, Université Laval, Quebec City, Quebec, G1R 3S3, Canada.Manuel.Caruso@ crchudequebec.ulaval.ca
| | | |
Collapse
|
19
|
Maugeri AG, Barchitta M, Quattrocchi A, La Rosa MC, Caruso M, Panella M, Cianci A, Agodi A. Mediterranean diet, nutrient intakes and pregnancy: results from a Sicilian mother-child cohort. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx189.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- AG Maugeri
- Department GF Ingrassia, University of Catania, Catania, Italy
| | - M Barchitta
- Department GF Ingrassia, University of Catania, Catania, Italy
| | - A Quattrocchi
- Department GF Ingrassia, University of Catania, Catania, Italy
| | - MC La Rosa
- Department GF Ingrassia, University of Catania, Catania, Italy
| | - M Caruso
- Azienda Ospedaliero-Universitaria “Policlinico - Vittorio Emanuele”, Catania, Italy
| | - M Panella
- Azienda Ospedaliero-Universitaria “Policlinico - Vittorio Emanuele”, Catania, Italy
| | - A Cianci
- Azienda Ospedaliero-Universitaria “Policlinico - Vittorio Emanuele”, Catania, Italy
| | - A Agodi
- Department GF Ingrassia, University of Catania; AOU Policlinico V Emanuele, Catania, Italy
| |
Collapse
|
20
|
Adamo V, Ricciardi G, Schifano S, Russo A, Gebbia V, Blasi L, Giuffrida D, Scandurra G, Savarino A, Butera A, Borsellino N, Verderame F, Caruso M. Safety and efficacy of the treatment with Nab-paclitaxel in mEtastatic bREast cancer In elDerly patiEnts: NEREIDE study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Zizzadoro C, Caruso M, Punzi S, Crescenzo G, Zongoli F, Belloli C. A comparative study between responses of isolated bovine and equine digital arteries to vasoactive mediators. J Vet Pharmacol Ther 2017; 41:51-59. [DOI: 10.1111/jvp.12436] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Accepted: 06/07/2017] [Indexed: 01/17/2023]
Affiliation(s)
- C. Zizzadoro
- Division of Veterinary Pharmacology and Toxicology; Department of Veterinary Medicine; University of Bari; Valenzano Bari Italy
| | - M. Caruso
- Division of Veterinary Pharmacology and Toxicology; Department of Veterinary Medicine; University of Bari; Valenzano Bari Italy
| | - S. Punzi
- Division of Veterinary Pharmacology and Toxicology; Department of Veterinary Medicine; University of Bari; Valenzano Bari Italy
| | - G. Crescenzo
- Division of Veterinary Pharmacology and Toxicology; Department of Veterinary Medicine; University of Bari; Valenzano Bari Italy
| | | | - C. Belloli
- Division of Veterinary Pharmacology and Toxicology; Department of Veterinary Medicine; University of Bari; Valenzano Bari Italy
| |
Collapse
|
22
|
Napolitano G, Iacobellis A, Merla A, Niro G, Valvano MR, Terracciano F, Siena D, Caruso M, Ippolito A, Mannuccio PM, Andriulli A. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. Eur J Intern Med 2017; 38:79-82. [PMID: 27989373 DOI: 10.1016/j.ejim.2016.11.007] [Citation(s) in RCA: 80] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Revised: 10/21/2016] [Accepted: 11/08/2016] [Indexed: 12/13/2022]
Abstract
BACKGROUND In cirrhotics with low circulating platelets (PLT), restoration of normal cell counts has been traditionally recommended before invasive procedures. However, there is neither consensus on the PLT transfusion threshold nor evidence of its clinical efficacy. PATIENTS In order to fill this gap of knowledge, we prospectively collected and analyzed data on circulating PLT counts [and International Normalized Ratio (INR)] values in a case series of 363 cirrhotics scheduled to undergo invasive investigations. PLT and/or fresh-frozen plasma (FFP) units were infused at the discretion of the attending physician, and the occurrence of post-procedural bleeding was related to pre-and post-infusion results. RESULTS 852 Procedures were carried out in 363 cirrhotics sub-grouped according to the Child-Pugh-Turcotte (CPT) classification (class A/B/C: 124/154/85). The infusion of PLT and/or FFP improved only marginally circulating PLT counts and INR values. Ten post-procedural bleeds occurred in the whole case series, i.e. 1 episode every 85 procedures or every 36 patients. Post-procedural bleeding was unrelated to the PLT counts, to the degree of INR abnormalities, nor to the CPT classes, but was more frequent in patients who underwent repeated investigations. In the 10 patients with the most profound alterations in PLT and/or INR values, no post-procedural bleeding occurred. CONCLUSIONS In cirrhotic patients with low PLT and/or abnormal INR values undergoing invasive investigations, post-procedural bleeding was rare and unpredicted by PLT counts or abnormal INR values. In particular, the recommendation to infuse platelets when counts are <50×103/L is not substantiated by this case series of cirrhotic patients.
Collapse
Affiliation(s)
- Grazia Napolitano
- Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy
| | - Angelo Iacobellis
- Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy.
| | - Antonio Merla
- Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy
| | - Grazia Niro
- Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy
| | - Maria Rosa Valvano
- Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy
| | - Fulvia Terracciano
- Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy
| | - Domenico Siena
- Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy
| | - Mariangela Caruso
- Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy
| | - Antonio Ippolito
- Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy
| | - Pier Mannucci Mannuccio
- Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda, Policlinico Maggiore Hospital Foundation and University of Milan, Italy
| | - Angelo Andriulli
- Division of Gastroenterology, "Casa Sollievo Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Italy
| |
Collapse
|
23
|
Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali DG, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Giannarelli D, Cognetti F. Abstract P4-21-11: T-DM1 in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: T-DM1 showed remarkable activity in metastatic HER-2 positive breast cancer (mBC) and it was recently approved for clinical use in patients (pts) who previously failed Trastuzumab- and Taxanes-based therapies. Currently, little is known on the performance of T-DM1 in a “real life” scenario. Therefore, we investigated effectiveness and safety of T-DM1 in Italian daily practice.
Methods: Pts baseline characteristics and clinical outcome of pts with HER-2 positive mBC treated with T-DM1 between 2013 and 2015 at 20 Italian Institutions were retrospectively collected and analyzed.
Results: 300 pts were included in our analysis. Median age was 51 years (27-78); visceral metastases were present in 204 (68%) pts and brain metastases in 86 (29%). It is noteworthy that 111 (37%) pts received T-DM1 as pure second line, 83 (28%) as third line and 96 (32%) as further lines. Moreover 10 (3%) pts had T-DM1 as first line because disease recurrence occurred during or adjuvant trastuzumab of within 6 months of its completion. The overall response rate (ORR) was 40%, global disease control rate (gDCR) 64%, median progression-free survival (PFS) 7.0 months (C.I.95%: 5.6-8.4) and overall survival (OS) at 2 years 63%. Pts with 1, 2 and 3 or more metastatic site had OS at 2 years of 87%, 67% and 46%, respectively (p<0.0001). When T-DM1 was given as second line the PFS was 8.0 months and beyond second-line was 6.8 months. Interestingly, for 38 (13%) pts who progressed after Pertuzumab-plus trastuzumab and taxanes as first line treatment, ORR and gDCR were similar to pertuzumab-naïve patients (38% and 62%, respectively) However PFS was 5.0 months (C.I.95%: 4.3-5.7) compared to 9.0 (95% C.I. 5.5-12.4) achieved in pts not receiving a previous pertuzumab-based treatment. Most frequent grade ≥3 toxicities were thrombocytopenia (2.6%), alopecia (2.1%), hypertransaminasemia (2.2%), neutropenia (1.3%), asthenia (1.3%) and diarrhea (0.4%).
Conclusions: To our knowledge, this is the first real life, multicenter retrospective analysis evaluating efficacy and safety of T-DM1 in pretreated HER-2 positive mBC pts. We observed remarkable results in terms of PFS and OS, especially when T-DM1 was given early in the course of metastatic disease. Shortened PFS in patients progressing after pertuzumab suggest further analyses to better define possible molecular mechanisms of cross-resistences between two molecules. As a whole there was no evidence of significant or unexpected toxicities. Although these findings should be taken with caution due to the retrospective analysis and the different lines of previous treatment considered, we confirmed the potential therapeutic role of T-DM1 across a heterogeneous population of HER-2 positive mBC patients. The final analysis will be presented to the meeting.
Citation Format: Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali DG, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Giannarelli D, Cognetti F. T-DM1 in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-11.
Collapse
Affiliation(s)
- A Fabi
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - M De Laurentiis
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - M Caruso
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - E Valle
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - L Moscetti
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - D Santini
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - K Cannita
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - L Carbognin
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - M Ciccarese
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - R Rossello
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - G Arpino
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - V Leonardi
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - F Montemurro
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - N La Verde
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - DG Generali
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - A Zambelli
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - G Scandurra
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - M Russillo
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - I Paris
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - AM D'Ottavio
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - G Filippelli
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - M Giampaglia
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - S Stani
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - A Fabbri
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - D Alesini
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - D Giannarelli
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| | - F Cognetti
- Istituto Nazionale Tumori Regina Elena, Roma; Istituto Nazionale Tumori Fondazione Pascale, Napoli; CCO Humanitas, Catania; Ospedale Oncologico Armando Businco, Cagliari; Azienda Ospedaliero-Universitaria, Modena; Campus Bio Medico, Roma; Presidio Ospedaliero S. Salvatore, L'Aquila; Azienda Universitaria Integrata, Verona; Ospedale Vito Fazzi, Lecce; Ospedale S. Vincenzo, Taormina; Università Federico II, Napoli; ARNAS Civico, Palermo; Fondazione del Piemonte per l'Oncologia, Candiolo; Ospedale S. Raffaele, Milano; Istituti Ospedalieri, Cremona; Azienda Ospedaliera Ospedali Riuniti, Bergamo; Ospedale Oncologico, Catania; Ospedale Oncologico, Lucca; Università Cattolica del Sacro Cuore Agostino Gemelli, Roma; Ospedale S. Giovanni Addolorata, Roma; Ospedale S. Francesco di Paola, Paola; Azienda Ospedaliera S. Carlo, Potenza; Ospedale S. Spirito, Roma; Ospedale Belcolle, Viterbo
| |
Collapse
|
24
|
Marinari S, De Iuliis V, Dadorante V, Colella S, Marino A, Nunziata A, Flati V, Caruso M, Pennelli A, De Benedetto F, Matera S, Capodifoglio S, Martinotti S, Caputi S, Toniato E. Cytokine modulation in patients with idiopathic pulmonary fibrosis undergoing treatment with steroids, immunosuppressants, and IFN-γ 1b. J BIOL REG HOMEOS AG 2017; 31:59-69. [PMID: 28337871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of unknown etiology and pathogenic mechanisms. From an etiopathogenic point of view, alveolar macrophages play a key role in accumulation of fibroblasts and deposition of collagen and extracellular matrix by releasing specific cytokines and inflammatory mediators. IPF seems to be also associated with circulating fibrocytes, which might be involved with an abnormal pulmonary vascular repair and remodeling. Based on its hypothesized pathologic mechanisms, anti-inflammatory, anti-fibrotic and immunosuppressive therapies are often used. For these reasons, Interferon-g (IFN-g) has been used to exploit its activity on macrophages and fibroblasts. The aim of this study was to investigate the response to corticosteroids and/or IFN-g 1b treatments based on pulmonary function tests and on inflammatory cytokine patterns of expression on bronchoalveolar lavage (BAL), at baseline and during and after the therapies. Unlike previous studies, we analyzed a period of therapy longer than 1 year. Our results demonstrated the effectiveness of IFN-γ in a group of IPF patients in whom the treatment was prolonged for over a year. These data suggest a positive role of IFN-γ; treatment in patients in the initial stage of the disease.
Collapse
Affiliation(s)
- S Marinari
- SS Annunziata University Hospital, Unit of Pneumology, Chieti, Italy
| | - V De Iuliis
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - V Dadorante
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti
| | - S Colella
- SS Annunziata University Hospital, Unit of Pneumology, Chieti, Italy
| | - A Marino
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - A Nunziata
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - V Flati
- Department of Biotechnological and Applied Clinical Sciences, University of LAquila, Italy
| | - M Caruso
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - A Pennelli
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti
| | - F De Benedetto
- AIMAR (Interdisciplinary Association for the study of Respiratory Diseases), Arona (NO), Italy
| | - S Matera
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - S Capodifoglio
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - S Martinotti
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - S Caputi
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| | - E Toniato
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy
| |
Collapse
|
25
|
Caruso M, Fanchiotti H, García Canal CA, Mayosky M, Veiga A. The quantum CP-violating kaon system reproduced in the electronic laboratory. Proc Math Phys Eng Sci 2016. [DOI: 10.1098/rspa.2016.0615] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The equivalence between the Schrödinger dynamics of a quantum system with a finite number of basis states and a classical dynamics is realized in terms of electric networks. The isomorphism that connects in a univocal way both dynamical systems was applied to the case of neutral mesons, kaons in particular, and the class of electric networks univocally related to the quantum system was analysed. Moreover, under
CPT
invariance, the relevant
ϵ
parameter that measures
CP
violation in the kaon system is reinterpreted in terms of network parameters. All these results were explicitly shown by means of both a numerical simulation of the implied networks and by constructing the corresponding circuits.
Collapse
Affiliation(s)
- M. Caruso
- Laboratorio de Física Teórica, Departamento de Física, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, IFLP-CONICET, C.C. 67, 1900 La Plata, Argentina
| | - H. Fanchiotti
- Laboratorio de Física Teórica, Departamento de Física, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, IFLP-CONICET, C.C. 67, 1900 La Plata, Argentina
| | - C. A. García Canal
- Laboratorio de Física Teórica, Departamento de Física, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, IFLP-CONICET, C.C. 67, 1900 La Plata, Argentina
| | - M. Mayosky
- LEICI, Departamento de Electrotecnia Facultad de Ingeniería, Universidad Nacional de La Plata, La Plata, Argentina. Comisión de Investigaciones Científicas de la Provincia de Buenos Aires-CICpBA, , Argentina
| | - A. Veiga
- LEICI, Departamento de Electrotecnia Facultad de Ingeniería, Universidad Nacional de La Plata, CONICET, La Plata, Argentina
| |
Collapse
|
26
|
Imburgia A, Romano P, Caruso M, Viola F, Miceli R, Riva Sanseverino E, Madonia A, Schettino G. Contributed Review: Review of thermal methods for space charge measurement. Rev Sci Instrum 2016; 87:111501. [PMID: 27910572 DOI: 10.1063/1.4968029] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The space charge accumulation phenomenon has garnered great interest over the last two decades because of the increased use of direct current in high voltage electrical systems. In this context, a significant relevance has been achieved by the thermal methods, used for solid dielectrics. This paper presents a review of this non-destructive measurement system used for the measurement of space charge. The thermal pulse method, the thermal step method, and the laser intensity modulation method are described. For each configuration, the principle of operation, the thicknesses analyzed, and the spatial resolution are described, reporting also the main related applications.
Collapse
Affiliation(s)
- A Imburgia
- DEIM, University of Palermo, Palermo 90128, Italy
| | - P Romano
- DEIM, University of Palermo, Palermo 90128, Italy
| | - M Caruso
- DEIM, University of Palermo, Palermo 90128, Italy
| | - F Viola
- DEIM, University of Palermo, Palermo 90128, Italy
| | - R Miceli
- DEIM, University of Palermo, Palermo 90128, Italy
| | | | - A Madonia
- DEIM, University of Palermo, Palermo 90128, Italy
| | - G Schettino
- DEIM, University of Palermo, Palermo 90128, Italy
| |
Collapse
|
27
|
Wojnilowicz M, Tortora M, Bobay BG, Santiso E, Caruso M, Micheli L, Venanzi M, Menegatti S, Cavalieri F. A combined approach for predicting the cytotoxic effect of drug-nanoaggregates. J Mater Chem B 2016; 4:6516-6523. [PMID: 32263696 DOI: 10.1039/c6tb02105k] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
We present a combined spectroscopic and computational approach aimed to elucidate the mechanism of formation and activity of etoposide nanoaggregates upon release from dextran-etoposide conjugates. Etoposide is an anticancer drug that inhibits cell growth by blocking Topoisomerase II, the key enzyme involved in re-ligation of the DNA chains during the replication process. In silico and spectroscopic analysis indicate that released etoposide nanoaggregates have a different structure, stability, and bioactivity, which depend on the pH experienced during the release. Molecular dynamics simulation and in silico docking of etoposide dimers suggest that the aggregation phenomena inhibit etoposide bioactivity, yet without drastically preventing Topoisomerase II binding. We correlated the diminished cytotoxic activity exerted by dextran-etoposide conjugates on the A549 lung cancer cells, compared to the free drug, to the formation and stability of drug nanoaggregates.
Collapse
Affiliation(s)
- M Wojnilowicz
- Department of Chemical and Biomolecular Engineering, The University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Tan EH, Banna G, Ramlau R, Ceresoli G, Camerini A, Milanowski J, Caruso M, Landreau P, Vedovato JC, Kowalski D. Final results of a phase II study of oral vinorelbine (NVBo) monotherapy in patients (pts) with advanced EGFR-positive non-small-cell lung cancer (NSCLC) after failure of EGFR-TKI in first line (NAVoTRIAL 2). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Spoto G, De Iuliis V, Petrini M, Flati V, Di Gregorio J, Vitale D, Caruso M, Dadorante V, Ciarmoli M, Robuffo I, Martinotti S, Toniato E. Effect of low energy light irradiation by light emitting diode on U937 cells. J BIOL REG HOMEOS AG 2016; 30:997-1007. [PMID: 28078845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Photobiomodulation (PBM) can induce a set of different biological modulators either in vitro or in vivo. Experimental evidence has highlighted the role of light effects on the mechanisms related to inflammation, apoptosis and autophagy. The goal of this project was the evaluation of PBM on U937, an established cell line of histiocytic lymphoma origin. Several aspects of modulation of proinflammatory pathways were analyzed and autophagic and proapoptotic mechanisms related to low laser light exposure of cells were studied. As a source of low energy light emission, we used an NIR-LED device, characterized by an 880 nm-wavelength as light source. Flow cytometry analysis was performed on supernatants of controls and treated U937 cells to detect inflammatory cytokine levels. In order to evaluate NF-kB and caspase3 expressions, Western blot analysis was performed according to standard procedures. In this report, we show the effect of PBM on a monocyte/macrophage established tumor cell line (U-937). We demonstrate that LED exposure, in the presence or absence of lipopolysaccharide (LPS), activates cell degranulation, increased expression of Interleukin-8 (IL-8) and modulation of beta galactosidase activity. Evidence shows that the well-known pro-inflammatory nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and the apoptotic marker (caspase3/cleaved-caspase3 ratio) are up-regulated in response to a proinflammatory biochemical pathway.
Collapse
Affiliation(s)
- G Spoto
- Department of Medical, Oral and Biotechnological Sciences, University G. dAnnunzio of Chieti, Italy
| | - V De Iuliis
- Unit of Predictive Medicine and Clinical Molecular biology, SS Annunziata University Hospital, ASL Lanciano-Vasto-Chieti, University G dAnnunzio, Chieti, Italy
| | - M Petrini
- Department of Medical, Oral and Biotechnological Sciences, University G. dAnnunzio of Chieti, Italy
| | - V Flati
- Department of Biotechnological and Applied Clinical Sciences, University of LAquila, LAquila, Italy
| | - J Di Gregorio
- Department of Biotechnological and Applied Clinical Sciences, University of LAquila, LAquila, Italy
| | - D Vitale
- Department of Medical, Oral and Biotechnological Sciences, University G. dAnnunzio of Chieti, Italy
| | - M Caruso
- Department of Medical, Oral and Biotechnological Sciences, University G. dAnnunzio of Chieti, Italy
| | - V Dadorante
- Unit of Predictive Medicine and Clinical Molecular biology, SS Annunziata University Hospital, ASL Lanciano-Vasto-Chieti, University G dAnnunzio, Chieti, Italy
| | - M Ciarmoli
- CNR, Institute of Molecular Genetics, Section of Chieti, Chieti, Italy
| | - I Robuffo
- CNR, Institute of Molecular Genetics, Section of Chieti, Chieti, Italy
| | - S Martinotti
- Unit of Predictive Medicine and Clinical Molecular biology, SS Annunziata University Hospital, ASL Lanciano-Vasto-Chieti, University G dAnnunzio, Chieti, Italy
| | - E Toniato
- Department of Medical, Oral and Biotechnological Sciences, University G. dAnnunzio of Chieti, Italy
| |
Collapse
|
30
|
De Iuliis V, Ursi S, Di Tommaso LM, Caruso M, Marino A, D'Ercole S, Caputi S, Sinjari B, Festa F, Macri M, Martinotti S, Vitullo G, Toniato E. Comparative molecular analysis of bacterial species associated with periodontal disease. J BIOL REG HOMEOS AG 2016; 30:1209-1215. [PMID: 28078876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Periodontal disease is an inflammatory disorder affecting the supporting teeth structures, including gingiva, periodontal ligament and alveolar bone, causing loss of connective tissue, reabsorption of alveolar bone and formation of periodontal pockets. The aim of this study is to find a correlation between bacterial growth and periodontal disease. Fifty-seven patients aged between 21 and 65 years, median age 46 years, were enrolled. According to gingival pocket depth, ranging from 3 to 7 mm, patients were divided into two groups: the first (30 patients, 53%) with deep pockets ³ 5 mm and the second (27 patients, 47%) less than 5 mm. The samples taken were processed for microbiological analysis by absolute quantitative real-time Taq-Man technique. Patients affected by periodontal disease were 32 (56%) and patients with gingival bleeding were 35 (61%). This data showed that the presence, the type and the bacterial load in gingival pockets were strongly correlated with gingival depth, periodontal disease and gingival bleeding. Quantitative microbiological analysis is a key point to improve patient compliance, allowing to choose the specific antibiotic treatment. avoiding antibiotic resistance and ensuring the successful outcome of therapy for periodontal disease.
Collapse
Affiliation(s)
- V De Iuliis
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - S Ursi
- SS Annunziata University Hospital, Unit of Clinical Molecular Biology and Predictive Medicine, University of Chieti, ASL Lanciano-Vasto-Chieti, Chieti, Italy
| | - L M Di Tommaso
- SS Annunziata University Hospital, Unit of Clinical Molecular Biology and Predictive Medicine, University of Chieti, ASL Lanciano-Vasto-Chieti, Chieti, Italy
| | - M Caruso
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - A Marino
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - S D'Ercole
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - S Caputi
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - B Sinjari
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - F Festa
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - M Macri
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| | - S Martinotti
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
- SS Annunziata University Hospital, Unit of Clinical Molecular Biology and Predictive Medicine, University of Chieti, ASL Lanciano-Vasto-Chieti, Chieti, Italy
| | - G Vitullo
- SS Annunziata University Hospital, Unit of Clinical Molecular Biology and Predictive Medicine, University of Chieti, ASL Lanciano-Vasto-Chieti, Chieti, Italy
| | - E Toniato
- Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy
| |
Collapse
|
31
|
Aiello D, Patti S, Alì M, Sanò M, Virgilio S, Taibi E, Di Leo V, Fallica G, Caruso M, Aiello R. Evaluation of quality of life in early breast cancer disease free survivors. a cross sectional survey. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Caruso M, Latorre L, Santagada G, Fraccalvieri R, Miccolupo A, Sottili R, Palazzo L, Parisi A. Methicillin-resistant Staphylococcus aureus (MRSA) in sheep and goat bulk tank milk from Southern Italy. Small Rumin Res 2016. [DOI: 10.1016/j.smallrumres.2015.12.023] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
33
|
De Cesare A, Parisi A, Giacometti F, Serraino A, Piva S, Caruso M, De Santis EPL, Manfreda G. Multilocus sequence typing of Arcobacter butzleri isolates collected from dairy plants and their products, and comparison with their PFGE types. J Appl Microbiol 2015; 120:165-74. [PMID: 26481316 DOI: 10.1111/jam.12977] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2015] [Revised: 10/09/2015] [Accepted: 10/09/2015] [Indexed: 11/26/2022]
Abstract
AIMS The present study aimed to determine, by multilocus sequence type (MLST), the heterogeneity level of Arcobacter butzleri isolates and to compare MLST and pulsed-field gel electrophoresis (PFGE) in terms of discriminatory power (DI) as well as unidirectional and bi-directional concordance. METHODS AND RESULTS Arcobacter butzleri isolates (N = 133) from dairy products and environmental samples, collected from dairy plants, were characterized by MLST and PFGE with SacII and classified in 29 sequence types (STs), 47 PFGE and 62 type strains (TS). Among the 119 alleles, 19 were previously unreported and the same for all the STs but two. A significant linkage disequilibrium was detected when the complete ST data set was analysed The DIs of MLST, PFGE and their combination were 0·937, 0·953 and 0·965 respectively. The adjusted Wallace coefficients between MLST and PFGE as well as PFGE and MLST were 0·535 and 0·720 respectively; the adjusted Rand coefficient was 0·612. CONCLUSIONS The A. butzleri studied population showed recombination to some degree. PFGE showed a DI higher than MLST. Both methods presented good concordance. The TS analysis seems to show persistence of the same strain on time and possible cross-contaminations between food and environmental sites. SIGNIFICANCE AND IMPACT OF THE STUDY This study provides insights in the A. butzleri population found in raw milk, cheese, and dairy production plants. The data suggest that MLST and PFGE genotypes correlate reasonably well, although their combination results in optimal resolution.
Collapse
Affiliation(s)
- A De Cesare
- Department of Agricultural and Food Sciences, University of Bologna, Ozzano dell'Emilia, Italy
| | - A Parisi
- Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata, Putignano, Italy
| | - F Giacometti
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Italy
| | - A Serraino
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Italy
| | - S Piva
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Italy
| | - M Caruso
- Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata, Putignano, Italy
| | - E P L De Santis
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - G Manfreda
- Department of Agricultural and Food Sciences, University of Bologna, Ozzano dell'Emilia, Italy
| |
Collapse
|
34
|
Caruso M, Jarne C. Equivalent Markov processes under gauge group. Phys Rev E Stat Nonlin Soft Matter Phys 2015; 92:052132. [PMID: 26651671 DOI: 10.1103/physreve.92.052132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Indexed: 06/05/2023]
Abstract
We have studied Markov processes on denumerable state space and continuous time. We found that all these processes are connected via gauge transformations. We have used this result before as a method to resolve equations, included the case in a previous work in which the sample space is time-dependent [Phys. Rev. E 90, 022125 (2014)]. We found a general solution through dilation of the state space, although the prior probability distribution of the states defined in this new space takes smaller values with respect to that in the initial problem. The gauge (local) group of dilations modifies the distribution on the dilated space to restore the original process. In this work, we show how the Markov process in general could be linked via gauge (local) transformations, and we present some illustrative examples for this result.
Collapse
Affiliation(s)
- M Caruso
- Departamento de Física Teórica y del Cosmos, Universidad de Granada, Campus de Fuentenueva, Granada (18071), Spain
| | - C Jarne
- Instituto de Física de Buenos Aires - CONICET Facultad de Ciencias Exactas y Naturales. Pabellón I Ciudad Universitaria Post Code:1428. Buenos Aires - Argentina
| |
Collapse
|
35
|
Adamo V, Ricciardi G, Franchina V, Ferraro G, Caruso M, Bronte G, Banna G, Spadaro P, Savarino A, Iacono C, Soto Parra H, Spada M, Safina V, Blasi L, Zerilli F, Prestifilippo A, Giannitto-Giorgio C, Alberio D, Cottini L, Russo A. Multicenter study of the eValuation of Eribulin (E) use in Sicily in metastatic breast cancer (MBC): A Prospective RegistrY (VESPRY trial). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Ricciardi G, Adamo B, Barresi V, Ieni A, Franchina T, Caruso M, Zacchia A, Fazzari C, Tuccari G, Adamo V. 1893 The role of Androgen Receptor, E-cadherin and Ki67 as novel prognostic markers in Triple Negative Breast Cancer (TNBC). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30843-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
37
|
|
38
|
Guettari N, Loubière L, Caruso M, Klatzmann D. Genetic pharmacomodulation of nucleoside analogues and gene therapy for AIDS and cancer. Antibiot Chemother (1971) 2015; 48:198-204. [PMID: 8726526 DOI: 10.1159/000425178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- N Guettari
- Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, CNRS ERS 107, Hôpital de la Pitié-Salpêtrière, Paris, France
| | | | | | | |
Collapse
|
39
|
Cappa M, Caruso M, Saggese G, Salerno MC, Tonini G. GH therapy in transition age: state of the art and future perspectives. MINERVA ENDOCRINOL 2015; 40:23-35. [PMID: 25660320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Growth hormone (GH) has been recently approved by the Italian Health Authorities for use in transition patients with childhood onset-growth hormone deficiency (CO-GHD). GH in addition to promote linear growth influences several key metabolic processes. In particular, in the transition period, from late adolescent to early adulthood, GH plays an important role in the achievement of a complete somatic development including body composition, muscle mass maturation, full skeletal mineralization and reproductive maturation, as well as in the prevention of metabolic and cardiovascular risk. Therefore, GH replacement should be restarted if a GH stimulation test at the re-evaluation fulfills established criteria. Endocrinologists experienced in the care of GHD adolescent patients held a workshop in Rome, Italy in July 2012 to review in detail the literature data and compare experiences of five Italian endocrinological centers on the negative consequences of interrupting GH treatment and the positive effects of continued GH replacement on intermediary metabolism, heart, muscle, pubertal development, and bone. The aim of the meeting was to delineate the state of the art on GH therapy in transition age and provide suggestions to pediatric and adult endocrinologists for a smooth transition care.
Collapse
Affiliation(s)
- M Cappa
- Unit of Endocrinology and Diabetic Bambino Gesù Children's Hospital IRCCS, Rome, Italy -
| | | | | | | | | |
Collapse
|
40
|
Caruso M, Check JH. Absence of blood type A or AB may be associated with diminished oocyte reserve. CLIN EXP OBSTET GYN 2015; 42:426. [PMID: 26411203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
PURPOSE To determine if blood type A protects against developing diminished oocyte reserve. MATERIALS AND METHODS Retrospective evaluation of incidence of blood type A (or AB) in women with normal oocyte reserve (day 3 serum follicle stimulating hormone (FSH) < or = 11 mIU/ml) vs. diminished oocyte reserve (FSH > or = 18 mIU/ml). RESULTS Five hundred forty-seven of 1,232 (44.4%) women with normal reserve had blood type A or AB vs. 33.8% (44/130) with diminished oocyte reserve (p = 0.027, chi-square). CONCLUSIONS Lack of blood type A or AB may link to some other gene that may be responsible for premature depletion of oocytes.
Collapse
|
41
|
Carpinelli P, Amboldi N, Ballinari D, Re Depaolini S, Cucchi U, Canevari G, Caruso M, Galli R, Donati D, Isacchi A, Felder E, Montagnoli A, Galvani A. 517 Identification and characterization of selective MELK kinase inhibitors. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70643-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
42
|
Luca T, Barresi V, Privitera G, Musso N, Caruso M, Condorelli DF, Castorina S. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Prolif 2014; 47:435-47. [PMID: 25131935 DOI: 10.1111/cpr.12125] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Accepted: 06/20/2014] [Indexed: 12/13/2022] Open
Abstract
OBJECTIVES Overexpression or constitutive activation of epidermal growth factor receptors (EGFR) is involved in growth of human cancers. We investigated effects of EGFR and HER-2 blockade in colon cancer cell lines using cetuximab and trastuzumab, with the aim of developing novel approaches to cancer therapy. MATERIALS AND METHODS We studied effects of treatment on cell growth, cell cycle distribution, induction of apoptosis, changes in EGFR and HER-2 mRNA-protein expression and EGFR and HER-2 gene copy number in Caco-2, HT-29 and HCT-116 cells. RESULTS Treatment of cells resulted in no effect in one of the three cell lines and in inhibition of cell proliferation in a time- and dose-dependent manner in the other two, with modulation of EGFR and HER-2 mRNA and protein levels. Differences in sensitivity to cetuximab and trastuzumab were observed. Treatment induced specific changes in cell cycle distribution in both cell lines affected, while apoptosis was not increased. Fluorescence in situ hybridization analysis revealed abnormal copy number of two genes resulting from aneuploidy; this was not responsible for different sensitivity to combination between the two cell lines. CONCLUSIONS Targeting EGFR and HER-2 simultaneously could have useful applications in colorectal cancer treatment. To improve pharmacological efficacy of cetuximab and trastuzumab combination, molecular mechanisms involved in their activity need to be elucidated.
Collapse
Affiliation(s)
- T Luca
- Fondazione Mediterranea "G.B. Morgagni", 95125, Catania, Italy
| | | | | | | | | | | | | |
Collapse
|
43
|
Caruso M, Jarne C. Markov-chain approach to the distribution of ancestors in species of biparental reproduction. Phys Rev E Stat Nonlin Soft Matter Phys 2014; 90:022125. [PMID: 25215707 DOI: 10.1103/physreve.90.022125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/21/2013] [Indexed: 06/03/2023]
Abstract
We studied how to obtain a distribution for the number of ancestors in species of sexual reproduction. Present models concentrate on the estimation of distributions repetitions of ancestors in genealogical trees. It has been shown that it is not possible to reconstruct the genealogical history of each species along all its generations by means of a geometric progression. This analysis demonstrates that it is possible to rebuild the tree of progenitors by modeling the problem with a Markov chain. For each generation, the maximum number of possible ancestors is different. This presents huge problems for the resolution. We found a solution through a dilation of the sample space, although the distribution defined there takes smaller values with respect to the initial problem. In order to correct the distribution for each generation, we introduced the invariance under a gauge (local) group of dilations. These ideas can be used to study the interaction of several processes and provide a new approach on the problem of the common ancestor. In the same direction, this model also provides some elements that can be used to improve models of animal reproduction.
Collapse
Affiliation(s)
- M Caruso
- Departamento de Física Teórica y del Cosmos, Universidad de Granada, Campus de Fuentenueva, Granada (18071), España
| | - C Jarne
- Departamento de Física, Facultad de Ciencias Exactas, IFLP-CONICET, Universidad Nacional de La Plata, La Plata (1900), C.C.67, Argentina
| |
Collapse
|
44
|
Incalcaterra E, Caruso M, Lo Presti R, Caimi G. Myocardial infarction in young adults: risk factors, clinical characteristics and prognosis according to our experience. Clin Ter 2014; 164:e77-82. [PMID: 23698218 DOI: 10.7417/ct.2013.1535] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVES Myocardial infarction is a relatively unusual phenomenon in young subjects. The aim if this work is to characterize the risk profile and factors influencing outcomes of these patients since it makes possible to manage prevention interventions. PATIENTS AND METHODS We examined cardiovascular risk factors, clinical presentation, angiographic picture and outcome of a group of young patients hospitalized for a myocardial infarction. We enrolled 121 young patients consecutively admitted to our hospital for a myocardial infarction and examined them not only at the initial stage, but also after 3 months and one year; finally a long-term telephonic follow up was performed, when possible. RESULTS We found some peculiarity making these patients quite different from the older ones who develop a myocardial infarction: cigarettes smoking, family history of ischemic heart disease and hyperlipidemia were the most frequent cardiovascular risk factors, while diabetes and hypertension were less represented; moreover coronary angiography showed more frequently a less extensive coronary atherosclerosis. Patients who developed a cardiovascular event at follow-up presented a significantly higher prevalence of hypertension and obesity and a significantly lower frequency of healthy coronary arteries and of previous revascularization. CONCLUSIONS Myocardial infarction in young adults presents several peculiarities, represented not only by the risk profile, but also by the angiographic picture and the prognosis. Considering the long life expectancy of the involved population, the essential role of preventive interventions should be strongly underlined.
Collapse
Affiliation(s)
- E Incalcaterra
- Department of Internal and Specialistic Medicine, University of Palermo, Palermo Italy.
| | | | | | | |
Collapse
|
45
|
Agodi A, Barchitta M, Quattrocchi A, Corallo T, Venticinque V, Caruso M. Access to prenatal cytogenetic diagnosis in Catania: a retrospective survey. Ann Ig 2013; 25:529-37. [PMID: 24284539 DOI: 10.7416/ai.2013.1953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND To determine the incidence of chromosome abnormalities (CAs) in prenatal cytogenetic diagnosis, to describe and compare indications in Italian and migrant women, and to assess the level of compliance with published national guidelines. METHODS A retrospective analysis of 7806 amniotic fluid samples (AFS) and 228 chorionic villi samples (CVS) was conducted. RESULTS Advanced maternal age was the most common indication. CAs incidence was 3.1 per 100 AFS, and 12.6 per 100 CVS. Only parental chromosome rearrangement and ultrasound abnormalities were significantly associated with CA occurrence (RR= 20.15 95%CI: 11.96-33.96; RR= 4.33; 95%CI: 2.95-6.36, respectively). Both in amniocentesis and in chorionic villi sampling CA incidence was significantly higher when performed according to the national guidelines, than for other reasons. Incidence data for trisomy 21, trisomy 18 and inversions were significantly higher than those reported in a previous Italian report. CONCLUSIONS Increased maternal age may explain, at least in part, the increase by time of CAs, although an excess was shown in our population independently from it. Our results show that advanced maternal age may not be sufficient as a single criterion for prenatal diagnosis, and suggesting a future revision of national clinical indications is suggested.
Collapse
Affiliation(s)
- A Agodi
- Department GF Ingrassia, University of Catania, Catania, Italy
| | | | | | | | | | | |
Collapse
|
46
|
Maisano R, Caristi N, Mare M, Bottari M, Adamo V, Mafodda A, Calogero M, Caruso M, Nardi M. Protective Effect of Leuprolide on Ovarian Function in Young Women Treated with Adjuvant Chemotherapy for Early Breast Cancer: A Multicenter Phase II Study. J Chemother 2013; 20:740-3. [DOI: 10.1179/joc.2008.20.6.740] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
47
|
Caruso M, Placidi E, Gatto E, Mazzuca C, Stella L, Bocchinfuso G, Palleschi A, Formaggio F, Toniolo C, Venanzi M. Fibrils or Globules? Tuning the Morphology of Peptide Aggregates from Helical Building Blocks. J Phys Chem B 2013; 117:5448-59. [DOI: 10.1021/jp400009j] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
| | - E. Placidi
- Istituto di Struttura della Materia, CNR, 00133 Roma, Italy
| | | | | | | | | | | | - F. Formaggio
- ICB, Padova Unit, CNR, Dipartimento
di Scienze Chimiche, Università di Padova, Padova, Italy
| | - C. Toniolo
- ICB, Padova Unit, CNR, Dipartimento
di Scienze Chimiche, Università di Padova, Padova, Italy
| | | |
Collapse
|
48
|
Parisi A, Latorre L, Fraccalvieri R, Miccolupo A, Normanno G, Caruso M, Santagada G. Occurrence of Listeria spp. in dairy plants in Southern Italy and molecular subtyping of isolates using AFLP. Food Control 2013. [DOI: 10.1016/j.foodcont.2012.05.036] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Coppola G, Caccamo G, Bacarella D, Corrado E, Caruso M, Cannavò MG, Assennato P, Novo S. Vasospastic angina and scombroid syndrome: a case report. Acta Clin Belg 2012; 67:222-5. [PMID: 22897074 DOI: 10.2143/acb.67.3.2062661] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Scombroid syndrome is a fish poisoning characterised by the onset of symptoms compatible with a pseudoallergic reaction; it is rarely also responsible of signs and symptoms of acute coronary syndromes, as demonstrated in this case report.
Collapse
Affiliation(s)
- G Coppola
- U.O.C. di Cardiologia, Scuola di Specializzazione in Malattie dell'Apparato Cardiovascolare, Dipartimento di Medicina Interna, Malattie Cardiovascolari e Nefrourologiche, Policlinico Universitario Paolo Giaccone Palermo, Italia
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Sano M, Taibi E, Alì M, Chiarenza M, Clementi S, Caruso M, Aiello R. Efficacy and Safety of Trastuzumab in Small HER2 Positive Tumors. A Single Institution Experience. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32837-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|